

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
\_\_\_\_\_  
BEFORE THE PATENT TRIAL AND APPEAL BOARD  
\_\_\_\_\_

INNOPHARMA LICENSING, INC., INNOPHARMA LICENSING LLC,  
INNOPHARMA INC., INNOPHARMA LLC,  
MYLAN PHARMACEUTICALS INC., and MYLAN INC.  
Petitioner,

v.

SENJU PHARMACEUTICAL CO., LTD., BAUSCH & LOMB, INC., and  
BAUSCH & LOMB PHARMA HOLDINGS CORP.  
Patent Owner.

\_\_\_\_\_  
U.S. Patent No. 8,871,813 to Sawa *et al*  
Issue Date: October 28, 2014  
\_\_\_\_\_

Title: Aqueous Liquid Preparation Containing 2-Amino-3-(4-  
Bromobenzoyl)Phenylacetic Acid

*Inter Partes* Review No: IPR2016-00090

**DECLARATION OF PAUL A. LASKAR, PH.D.**

## TABLE OF CONTENTS

	<u>Page</u>
I. Introduction.....	1
II. List of documents I considered in formulating my opinion.....	7
III. My background and qualifications.....	11
IV. Person of ordinary skill in the art (POSA).....	15
V. The '813 patent .....	16
VI. State of the art as of January 2003 .....	18
A. Non-steroidal anti-inflammatory compounds were known and approved for ophthalmic use .....	18
B. BAC was the preservative of choice in ophthalmic formulations.....	22
C. It was known that non-ionic surfactants stabilized aqueous preparations containing an NSAID and BAC.....	23
D. Tyloxapol is a non-ionic surfactant that was known and widely used in ophthalmic formulations by January 2003.....	24
E. There is nothing inventive in the '813 patent in view of the prior art.....	30
VII. Obviousness of Claims 1-27 of the '813 patent.....	31
A. The basis of my analysis with respect to obviousness .....	31
B. Obviousness Ground 1 – Ogawa and Sallmann .....	33
1. Claim 1 .....	35
2. Claim 7 .....	38
3. Claim 13 .....	40
4. Further Discussion Regarding Claims 1, 7, and 13.....	42
5. Claims 2, 8 and 14—Sodium Sulfite.....	53
6. Claims 3 and 15—Bromfenac Sodium Salt .....	53
7. Claims 4, 6, 10, 12, 16, 18, 21, and 23—Concentrations .....	54
8. Claims 6, 12, 18, and 23—Additional Additives .....	59
9. Claims 5, 11, 17, and 22—pH Ranges .....	64
10. Claims 9, 19, and 20—Stability .....	65
11. Claims 24-26—No Preservative.....	67
12. Claim 27—Additional Additives.....	68
C. Obviousness Ground 2 – Ogawa and Sallmann and Fu .....	69

1.	Claims 1, 7, and 13 .....	70
2.	Claims 4, 6, 10, 12, 16, 18, and 21—Tyloxapol Concentrations .....	72
D.	Obviousness Ground 3 – Ogawa and Sallmann and Yasueda.....	74
1.	Claims 1, 7, and 13 .....	76
2.	Claims 4, 6, 10, 12, 16, 18, and 21—Tyloxapol Concentrations .....	77
VIII.	No Unexpected Results Over the Closest Prior Art.....	79
A.	Tyloxapol’s stabilization of an aqueous ophthalmic bromfenac preparation is not unexpected in view of the prior art.....	80
B.	Scope of Stabilizing Effects.....	83
IX.	No long-felt, unmet need existed for an ophthalmic NSAID preparation formulated with BAC.....	86
X.	The claimed bromfenac preparations were not met with skepticism .....	87
XI.	The claimed bromfenac ophthalmic formulations have not received any praises .....	88
XII.	Additional evidence of secondary considerations .....	88
XIII.	Conclusion.....	89

***I. Introduction***

1. I am over the age of eighteen (18) and otherwise competent to make this declaration.

2. I have been retained as an expert witness on behalf of Petitioner for the above-captioned *inter partes* review (“IPR”). I am being compensated for my time in connection with this IPR at my standard consulting rate, which is \$250 per hour. My compensation is in no way dependent on the outcome of this IPR.

3. I understand that the petition for *inter partes* review involves U.S. Patent No. 8,871,813 (“the ’813 patent”) (EX1001), which was issued on October 28, 2014, from U.S. Application No. 14/261,720 (“the ’720 application”), naming Shirou Sawa and Shuhei Fujita as the inventors. The ’720 application is a division of application No. 14/165,976 (“the ’976 application”), now U.S. Patent No. 8,754,131, which is a division of application No. 13/687,242 application (“the ’242 application”), now U.S. Patent No. 8,669,290, which is a division of application No. 13/353,653 (“the ’653 application”), now U.S. Pat. No. 8,497,304, which is a division of application No. 10/525,006 (“the ’006 application”), which was the U.S. National Stage of PCT Application No. PCT/JP2004/000350 (“the ’350 application”), filed on January 16, 2004, now U.S. Patent No. 8,129,431. The ’350 application claims priority to Japanese Application No. 2003-12427, filed on January 21, 2003. It is my understanding that the earliest possible priority date of

the '813 patent is January 21, 2003, the filing date of the Japanese priority application. I further understand that, according to the USPTO records, the '813 patent is currently assigned to Senju Pharmaceutical Co., Ltd. ("Senju," "the patentee," or "the patent owner").

4. Claim 1 of the '813 patent is reproduced below:

1. A stable aqueous liquid preparation consisting essentially of: (a) a first component; (b) a second component; wherein the first component is 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof; (c) boric acid; (d) sodium tetraborate; and (e) water; wherein the hydrate is at least one selected from a 1/2 hydrate, 1 hydrate, and 3/2 hydrate; the first component is the sole pharmaceutical active ingredient contained in the preparation and is present in the preparation at a concentration from about 0.05 w/v % to about 0.2 w/v %; the second component is tyloxapol and is present in said liquid preparation in an amount sufficient to stabilize said first component; and wherein said stable liquid preparation is formulated for ophthalmic administration.

(EX1001, 11:30-42).

5. Claims 2-6, 24, and 27 depend directly from Claim 1. Claims 2, 4-6, and 27 recite the concentrations of tyloxapol and/or bromfenac or its sodium salt, the pH of the preparations, and additional additives. Claim 3 recites that the bromfenac is a sodium salt. Claim 24 recites that the preparation does not include any preservative.

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.